Bone metastases are infrequent in patients with newly diagnosed prostate cancer: Analysis of their clinical and pathologic features

Urology

Volumn 68, Issue 2, 2006, Pages 362-366

  Salonia, Andrea ^a   Gallina, Andrea ^a   Camerota, Tommaso Ciro ^a   Picchio, Maria ^b   Freschi, Massimo ^a   DaPozzo, Luigi F ^a   Guazzoni, Giorgio ^a   Fazio, Ferruccio ^b   Rigatti, Patrizio ^a   Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CHI SQUARE TEST; CLINICAL FEATURE; CONTROLLED STUDY; GASTROESOPHAGEAL REFLUX; GLEASON SCORE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; NUCLEAR MEDICINE; PATHOLOGY; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; SCINTIGRAPHY; STATISTICAL SIGNIFICANCE; TUMOR BIOPSY;

AGED; BONE NEOPLASMS; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TECHNETIUM TC 99M MEDRONATE;

EID: 33746849782     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.02.009     Document Type: Article

References (29)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
2. Evans H.S., and Moller H. Recent trends in prostate cancer incidence and mortality in southeast England. Eur Urol 43 (2003) 337-341
3. Thurairaja R., McFarlane J., Traill Z., et al. State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int 94 (2004) 268-271
4. Carlin B.I., and Gerald L.A. The natural history, skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer 88 suppl (2000) 2989-2994
5. Rigaud J., Tiguert R., Le Normand L., et al. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 168 (2002) 1423-1426
6. Groot M.T., Boeken Kruger C.G., Pelger R.C., et al. Costs of prostate cancer, metastatic to the bone, in The Netherlands. Eur Urol 43 (2003) 226-232
7. Gomez P., Manoharan M., Kim S.S., et al. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy. when is it indicated?. BJU Int 94 (2004) 299-302
8. Kumar R., Zhuang H., and Alavi A. PET in the management of urologic malignancies. Radiol Clin North Am 42 (2004) 1141-1153
9. Oyen W.J., Witjes J.A., and Corstens F.H. Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. Eur Urol 40 (2001) 294-299
10. Abuzallouf S., Dayes I., and Lukka H. Baseline staging of newly diagnosed prostate cancer. a summary of the literature. J Urol 171 (2004) 2122-2127
11. Wolff J.M., Zimny M., Borchers H., et al. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?. Eur Urol 33 (1998) 376-381
12. Hammarsten J., and Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 13 (2004) 47-55
13. Ronquist G., Rodriguez L.A., Ruigomez A., et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 58 (2004) 50-56
14. Fitzpatrick A.L., Daling J.R., Furberg C.D., et al. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 11 (2001) 534-542
15. Liskow A.S., Neugut A.L., Benson M., et al. Multiple primary neoplasms in association with prostate cancer in black and white patients. Cancer 59 (1987) 380-384
16. Ray P., Guinan P., Sharifi R., et al. Prostate cancer and the multiple primary malignant neoplasm syndrome. Prostate 4 (1983) 513-522
17. Rossing M.A., Scholes D., Cushing-Haugen K.L., et al. Cimetidine use and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev 9 (2000) 319-323
18. Moller H., and Mellemgaard A. Prostate cancer incidence in cimetidine users. J Natl Cancer Inst 84 (1992) 359-360
19. Zhang J., Dai J., Qi Y., et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107 (2001) 1235-1244
20. Corey E., Brown L.G., Kiefer J.A., et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 65 (2005) 1710-1718
21. Young N., and Chole R. Cytokine-mediated bone resorption is cytochrome P-450 dependent. Student Research Award 1998. Otolaryngol Head Neck Surg 121 (1999) 708-712
22. 2 histamine receptors modulate osteoclastic resorption by different pathways. evidence obtained by using receptor antagonists in a rat synchronized resorption model. J Cell Physiol 173 (1997) 10-18
23. 2 antagonists. J Natl Cancer Inst 83 (1991) 1589
24. Galbraith R.A., and Michnovicz J.J. The effects of cimetidine on the oxidative metabolism of estradiol. N Engl J Med 321 (1989) 270-274
25. Michaelson M.D., Marujo R.M., and Smith M.R. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res 10 (2004) 2705-2708
26. Bruwer G., Heyns C.F., and Allen F.J. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol 35 (1999) 223-227
27. Lee N., Fawaaz R., Olsson C.A., et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 48 (2000) 1443-1446
28. Paiss T., Herkommer K., Bock B., et al. Association between the clinical presentation and epidemiological features of familial prostate cancer in patients selected for radical prostatectomy. Eur Urol 43 (2003) 615-621
29. Hubbard J.S., Rohrmann S., Landis P.K., et al. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 63 (2004) 253-258